U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900555) titled 'Hypofractionated Radiotherapy With MRI-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer' on Oct. 21.
Brief Summary: This prospective phase II study evaluated long-term disease control and side effects of a moderately hypofractionated radiotherapy protocol for men with high-risk prostate cancer. The protocol combined three strategies in one course of 25 treatments: a higher dose to the tumour seen on MRI (focal boost), a reduced dose to the uninvolved parts of the prostate, and elective irradiation of the pelvic lymph nodes, together with hormone therapy. Patients were included at Haukeland University Hospital, ...